The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2

A. Hatzakis; V. Chulanov; A. C. Gadano; C. Bergin; Z. Ben-Ari; J. Mossong; I. Schréter; O. Baatarkhuu; S. Acharya; I. Aho; A. C. Anand; M. I. Andersson; V. Arendt; P. Arkkila; K. Barclay; F. Bessone; S. Blach; N. Blokhina; C. R. Brunton; G. Choudhuri; L. Cisneros; E. A. Croes; Y. A. Dahgwahdorj; O. Dalgard; J. R. Daruich; N. R. Dashdorj; D. Davaadorj; R. J. De Knegt; M. De Vree; C. Estes; R. Flisiak; E. Gane; E. Gower; W. Halota; C. Henderson; P. Hoffmann; J. Hornell; D. Houlihan; S. Hrusovsky; P. Jarčuška; D. Kershenobich; K. Kostrzewska; P. Kristian; M. Leshno; Y. Lurie; A. Mahomed; N. Mamonova; N. Mendez-Sanchez; S. Norris; E. Nurmukhametova; P. Nymadawa; M. Oltman; J. Oyunbileg; Ts Oyunsuren; G. Papatheodoridis; N. Pimenov; N. Prabdial-Sing; M. Prins; S. Radke; A. Rakhmanova; K. Razavi-Shearer; H. W. Reesink; E. Ridruejo; R. Safadi; O. Sagalova; J. F. Sanchez Avila; R. Sanduijav; V. Saraswat; C. Seguin-Devaux; S. R. Shah; I. Shestakova; A. Shevaldin; O. Shibolet; M. O. Silva; S. Sokolov; M. Sonderup; K. Souliotis; C. W. Spearman; T. Staub; C. Stedman; E. A. Strebkova; D. Struck; V. Sypsa; K. Tomasiewicz; L. Undram; A. J. Van Der Meer; D. Van Santen; I. Veldhuijzen; F. G. Villamil; S. Willemse; E. Zuckerman; F. R. Zuure; P. Puri; H. Razavi

doi:10.1111/jvh.12351

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2

A. Hatzakis^*, V. Chulanov, A. C. Gadano, C. Bergin, Z. Ben-Ari, J. Mossong, I. Schréter, O. Baatarkhuu, S. Acharya, I. Aho, A. C. Anand, M. I. Andersson, V. Arendt, P. Arkkila, K. Barclay, F. Bessone, S. Blach, N. Blokhina, C. R. Brunton, G. ChoudhuriL. Cisneros, E. A. Croes, Y. A. Dahgwahdorj, O. Dalgard, J. R. Daruich, N. R. Dashdorj, D. Davaadorj, R. J. De Knegt, M. De Vree, C. Estes, R. Flisiak, E. Gane, E. Gower, W. Halota, C. Henderson, P. Hoffmann, J. Hornell, D. Houlihan, S. Hrusovsky, P. Jarčuška, D. Kershenobich, K. Kostrzewska, P. Kristian, M. Leshno, Y. Lurie, A. Mahomed, N. Mamonova, N. Mendez-Sanchez, S. Norris, E. Nurmukhametova, P. Nymadawa, M. Oltman, J. Oyunbileg, Ts Oyunsuren, G. Papatheodoridis, N. Pimenov, N. Prabdial-Sing, M. Prins, S. Radke, A. Rakhmanova, K. Razavi-Shearer, H. W. Reesink, E. Ridruejo, R. Safadi, O. Sagalova, J. F. Sanchez Avila, R. Sanduijav, V. Saraswat, C. Seguin-Devaux, S. R. Shah, I. Shestakova, A. Shevaldin, O. Shibolet, M. O. Silva, S. Sokolov, M. Sonderup, K. Souliotis, C. W. Spearman, T. Staub, C. Stedman, E. A. Strebkova, D. Struck, V. Sypsa, K. Tomasiewicz, L. Undram, A. J. Van Der Meer, D. Van Santen, I. Veldhuijzen, F. G. Villamil, S. Willemse, E. Zuckerman, F. R. Zuure, P. Puri, H. Razavi

^*Corresponding author for this work

Infection and Immunotherapy Research

Research output: Contribution to journal › Article › Research › peer-review

114 Citations (Scopus)

Abstract

Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

Original language	English
Pages (from-to)	26-45
Number of pages	20
Journal	Journal of Viral Hepatitis
Volume	22
Issue number	s1
DOIs	https://doi.org/10.1111/jvh.12351
Publication status	Published - 1 Jan 2015

Keywords

HCV
diagnosis
disease burden
epidemiology
hepatitis C
incidence
mortality
prevalence
treatment

Access to Document

10.1111/jvh.12351

Cite this

Hatzakis, A., Chulanov, V., Gadano, A. C., Bergin, C., Ben-Ari, Z., Mossong, J., Schréter, I., Baatarkhuu, O., Acharya, S., Aho, I., Anand, A. C., Andersson, M. I., Arendt, V., Arkkila, P., Barclay, K., Bessone, F., Blach, S., Blokhina, N., Brunton, C. R., ... Razavi, H. (2015). The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2. Journal of Viral Hepatitis, 22(s1), 26-45. https://doi.org/10.1111/jvh.12351

@article{2614263ee3b14181b14050078d4e1954,

title = "The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2",

abstract = "Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.",

keywords = "HCV, diagnosis, disease burden, epidemiology, hepatitis C, incidence, mortality, prevalence, treatment",

author = "A. Hatzakis and V. Chulanov and Gadano, {A. C.} and C. Bergin and Z. Ben-Ari and J. Mossong and I. Schr{\'e}ter and O. Baatarkhuu and S. Acharya and I. Aho and Anand, {A. C.} and Andersson, {M. I.} and V. Arendt and P. Arkkila and K. Barclay and F. Bessone and S. Blach and N. Blokhina and Brunton, {C. R.} and G. Choudhuri and L. Cisneros and Croes, {E. A.} and Dahgwahdorj, {Y. A.} and O. Dalgard and Daruich, {J. R.} and Dashdorj, {N. R.} and D. Davaadorj and {De Knegt}, {R. J.} and {De Vree}, M. and C. Estes and R. Flisiak and E. Gane and E. Gower and W. Halota and C. Henderson and P. Hoffmann and J. Hornell and D. Houlihan and S. Hrusovsky and P. Jar{\v c}u{\v s}ka and D. Kershenobich and K. Kostrzewska and P. Kristian and M. Leshno and Y. Lurie and A. Mahomed and N. Mamonova and N. Mendez-Sanchez and S. Norris and E. Nurmukhametova and P. Nymadawa and M. Oltman and J. Oyunbileg and Ts Oyunsuren and G. Papatheodoridis and N. Pimenov and N. Prabdial-Sing and M. Prins and S. Radke and A. Rakhmanova and K. Razavi-Shearer and Reesink, {H. W.} and E. Ridruejo and R. Safadi and O. Sagalova and {Sanchez Avila}, {J. F.} and R. Sanduijav and V. Saraswat and C. Seguin-Devaux and Shah, {S. R.} and I. Shestakova and A. Shevaldin and O. Shibolet and Silva, {M. O.} and S. Sokolov and M. Sonderup and K. Souliotis and Spearman, {C. W.} and T. Staub and C. Stedman and Strebkova, {E. A.} and D. Struck and V. Sypsa and K. Tomasiewicz and L. Undram and {Van Der Meer}, {A. J.} and {Van Santen}, D. and I. Veldhuijzen and Villamil, {F. G.} and S. Willemse and E. Zuckerman and Zuure, {F. R.} and P. Puri and H. Razavi",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2015",

month = jan,

day = "1",

doi = "10.1111/jvh.12351",

language = "English",

volume = "22",

pages = "26--45",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "s1",

}

Hatzakis, A, Chulanov, V, Gadano, AC, Bergin, C, Ben-Ari, Z, Mossong, J, Schréter, I, Baatarkhuu, O, Acharya, S, Aho, I, Anand, AC, Andersson, MI, Arendt, V, Arkkila, P, Barclay, K, Bessone, F, Blach, S, Blokhina, N, Brunton, CR, Choudhuri, G, Cisneros, L, Croes, EA, Dahgwahdorj, YA, Dalgard, O, Daruich, JR, Dashdorj, NR, Davaadorj, D, De Knegt, RJ, De Vree, M, Estes, C, Flisiak, R, Gane, E, Gower, E, Halota, W, Henderson, C, Hoffmann, P, Hornell, J, Houlihan, D, Hrusovsky, S, Jarčuška, P, Kershenobich, D, Kostrzewska, K, Kristian, P, Leshno, M, Lurie, Y, Mahomed, A, Mamonova, N, Mendez-Sanchez, N, Norris, S, Nurmukhametova, E, Nymadawa, P, Oltman, M, Oyunbileg, J, Oyunsuren, T, Papatheodoridis, G, Pimenov, N, Prabdial-Sing, N, Prins, M, Radke, S, Rakhmanova, A, Razavi-Shearer, K, Reesink, HW, Ridruejo, E, Safadi, R, Sagalova, O, Sanchez Avila, JF, Sanduijav, R, Saraswat, V, Seguin-Devaux, C, Shah, SR, Shestakova, I, Shevaldin, A, Shibolet, O, Silva, MO, Sokolov, S, Sonderup, M, Souliotis, K, Spearman, CW, Staub, T, Stedman, C, Strebkova, EA, Struck, D, Sypsa, V, Tomasiewicz, K, Undram, L, Van Der Meer, AJ, Van Santen, D, Veldhuijzen, I, Villamil, FG, Willemse, S, Zuckerman, E, Zuure, FR, Puri, P & Razavi, H 2015, 'The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2', Journal of Viral Hepatitis, vol. 22, no. s1, pp. 26-45. https://doi.org/10.1111/jvh.12351

TY - JOUR

T1 - The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2

AU - Hatzakis, A.

AU - Chulanov, V.

AU - Gadano, A. C.

AU - Bergin, C.

AU - Ben-Ari, Z.

AU - Mossong, J.

AU - Schréter, I.

AU - Baatarkhuu, O.

AU - Acharya, S.

AU - Aho, I.

AU - Anand, A. C.

AU - Andersson, M. I.

AU - Arendt, V.

AU - Arkkila, P.

AU - Barclay, K.

AU - Bessone, F.

AU - Blach, S.

AU - Blokhina, N.

AU - Brunton, C. R.

AU - Choudhuri, G.

AU - Cisneros, L.

AU - Croes, E. A.

AU - Dahgwahdorj, Y. A.

AU - Dalgard, O.

AU - Daruich, J. R.

AU - Dashdorj, N. R.

AU - Davaadorj, D.

AU - De Knegt, R. J.

AU - De Vree, M.

AU - Estes, C.

AU - Flisiak, R.

AU - Gane, E.

AU - Gower, E.

AU - Halota, W.

AU - Henderson, C.

AU - Hoffmann, P.

AU - Hornell, J.

AU - Houlihan, D.

AU - Hrusovsky, S.

AU - Jarčuška, P.

AU - Kershenobich, D.

AU - Kostrzewska, K.

AU - Kristian, P.

AU - Leshno, M.

AU - Lurie, Y.

AU - Mahomed, A.

AU - Mamonova, N.

AU - Mendez-Sanchez, N.

AU - Norris, S.

AU - Nurmukhametova, E.

AU - Nymadawa, P.

AU - Oltman, M.

AU - Oyunbileg, J.

AU - Oyunsuren, Ts

AU - Papatheodoridis, G.

AU - Pimenov, N.

AU - Prabdial-Sing, N.

AU - Prins, M.

AU - Radke, S.

AU - Rakhmanova, A.

AU - Razavi-Shearer, K.

AU - Reesink, H. W.

AU - Ridruejo, E.

AU - Safadi, R.

AU - Sagalova, O.

AU - Sanchez Avila, J. F.

AU - Sanduijav, R.

AU - Saraswat, V.

AU - Seguin-Devaux, C.

AU - Shah, S. R.

AU - Shestakova, I.

AU - Shevaldin, A.

AU - Shibolet, O.

AU - Silva, M. O.

AU - Sokolov, S.

AU - Sonderup, M.

AU - Souliotis, K.

AU - Spearman, C. W.

AU - Staub, T.

AU - Stedman, C.

AU - Strebkova, E. A.

AU - Struck, D.

AU - Sypsa, V.

AU - Tomasiewicz, K.

AU - Undram, L.

AU - Van Der Meer, A. J.

AU - Van Santen, D.

AU - Veldhuijzen, I.

AU - Villamil, F. G.

AU - Willemse, S.

AU - Zuckerman, E.

AU - Zuure, F. R.

AU - Puri, P.

AU - Razavi, H.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

AB - Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

KW - HCV

KW - diagnosis

KW - disease burden

KW - epidemiology

KW - hepatitis C

KW - incidence

KW - mortality

KW - prevalence

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84920270905&partnerID=8YFLogxK

U2 - 10.1111/jvh.12351

DO - 10.1111/jvh.12351

M3 - Article

C2 - 25560840

AN - SCOPUS:84920270905

SN - 1352-0504

VL - 22

SP - 26

EP - 45

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

IS - s1

ER -

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this